Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1995-10-12
|
pubmed:abstractText |
Interleukin-1 receptor antagonist (IL-1ra), a naturally occurring inhibitor of interleukin-1 (IL-1), blocks IL-1 binding to its receptors but has no agonistic activity. IL-1 is thought to play an important role in contact hypersensitivity (CHS), although the effects of exogenously administered IL-1 in CHS have been somewhat controversial. To clarify the role of IL-1 in CHS, we studied the effect of IL-1 receptor blockade using exogenous IL-1ra and evaluated these effects on CHS. We examined the in vivo effects of local administration of recombinant human IL-1ra in the murine CHS model. Local injection of IL-1ra to sensitized BALB/c mice just before challenge with dinitrofluorobenzene resulted in a significant reduction in the intensity of CHS responses, assessed by ear swelling. A dose-response study revealed that maximal inhibition of ear swelling (36% to 43%) was observed after intradermal injection of IL-1ra at doses of 10 to 100 micrograms/ear. This reduction in ear swelling in IL-1ra-injected ears consisted of less inflammatory cell infiltration and decreased edema in the dermis compared with controls. Suppression of CHS was observed when IL-1ra was applied in the 24-h interval preceding challenge with dinitrofluorobenzene, whereas no suppressive effect was observed when IL-1ra was applied 48 h before or after the challenge. Local administration of IL-1ra to naive mice 5 h before sensitization also suppressed CHS responses. However, IL-1ra injection did not suppress phenol-induced inflammation. These results suggest that IL-1ra is an effective inhibitor of both the sensitization and elicitation phases of CHS expression in mice, thus emphasizing the role of IL-1 as an immunologic potentiator of responses associated with CHS.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/IL1RN protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Il1rn protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin 1 Receptor Antagonist...,
http://linkedlifedata.com/resource/pubmed/chemical/Phenol,
http://linkedlifedata.com/resource/pubmed/chemical/Phenols,
http://linkedlifedata.com/resource/pubmed/chemical/Sialoglycoproteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0022-202X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
105
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
334-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7665908-Animals,
pubmed-meshheading:7665908-Dermatitis, Contact,
pubmed-meshheading:7665908-Drug Eruptions,
pubmed-meshheading:7665908-Female,
pubmed-meshheading:7665908-Interleukin 1 Receptor Antagonist Protein,
pubmed-meshheading:7665908-Mice,
pubmed-meshheading:7665908-Mice, Inbred BALB C,
pubmed-meshheading:7665908-Phenol,
pubmed-meshheading:7665908-Phenols,
pubmed-meshheading:7665908-Sialoglycoproteins,
pubmed-meshheading:7665908-Time Factors,
pubmed-meshheading:7665908-Treatment Outcome
|
pubmed:year |
1995
|
pubmed:articleTitle |
Interleukin-1 receptor antagonist suppresses contact hypersensitivity.
|
pubmed:affiliation |
Division of Dermatology, Sunnybrook Health Science Centre, University of Toronto, Canada.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|